CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
People›
Rifat Pamukcu
AddedMar 31, 2024
UpdatedOct 12, 2026
Rifat Pamukcu

Rifat Pamukcu

Founder & CEO, Midway Pharmaceuticals

Rifat Pamukcu's Career

Midway Pharmaceuticals

Midway Pharmaceuticals

Seed$500kSpring House, PA, US
Board Member· Board
Founder & CEO· C-Suite · Management
Founder

Leadership at Midway Pharmaceuticals

Harry AraderHarry AraderBoard Member
Mitchell FinkMitchell FinkBoard Member

Similar to Midway Pharmaceuticals

Outpost MedicineOutpost MedicineLexington, MA, USPharmaceuticals, Therapeuticsest. 2016Outpost MedicineLexington, MA, US · est. 2016

Outpost: A biopharmaceutical firm developing novel therapeutics for gastrointestinal and urologic disorders.

Series A · $61M12
MarvelBiomeMarvelBiomeWoburn, MA, USTherapeuticsest. 2019MarvelBiomeWoburn, MA, US · est. 2019

MarvelBiome: A biopharmaceutical company harnessing microbial power for innovative disease treatments.

Seed · $3.1M9
Bond BiosciencesBond BiosciencesNew York City, NY, USPharmaceuticals, Therapeuticsest. 2016Bond BiosciencesNew York City, NY, US · est. 2016

Bond Biosciences: A private biopharma firm developing non-absorbed oral therapeutics for human diseases.

Series B · $11.8M7
MuciMedMuciMedKalamazoo, MI, USDisease Treatmentest. 2005MuciMedKalamazoo, MI, US · est. 2005

Developing mucin proteins for GI disease treatment since 2005. Based in Kalamazoo, Michigan.

Angel · $200k6
Virion Therapeutics

Virion Therapeutics

Series A$14.1MNewark, DE, US
Board Member· Board

Leadership at Virion Therapeutics

Hildegund ErtlHildegund ErtlFounder
Bernard RudnickBernard RudnickBoard Member
Kathy HighKathy HighBoard Member
Bill BradfordBill BradfordBoard Member
Terry WrightTerry WrightBoard Member
Thomas PennThomas PennBoard Member

Similar to Virion Therapeutics

ViriomViriomSan Diego, CA, USHBV Treatments, HIV Treatmentsest. 2009ViriomSan Diego, CA, US · est. 2009

Viriom: A therapeutic biotech firm innovating treatments for HIV and Hepatitis B.

Series B · $35.4M200
Vir BiotechnologyVir BiotechnologySan Francisco, CA, USMedicines, Therapeuticsest. 2016Vir BiotechnologySan Francisco, CA, US · est. 2016

Vir Biotechnology, a clinical-stage firm, develops and commercializes treatments for viral and bacterial diseases in California.

Public · $908.6M576
TherabiolTherabiolSan Francisco, CA, USImmune Therapiesest. 2012TherabiolSan Francisco, CA, US · est. 2012

Therabiol, Inc.: A San Francisco-based biotech firm specializing in developing immune therapies for viral infections.

Seed · $150k5
IconOVir BioIconOVir BioSan Diego, CA, USOncolytic Virusest. 2018IconOVir BioSan Diego, CA, US · est. 2018

IconOVir Bio: A preclinical biotech firm innovating personalized oncolytic virus cancer therapies.

Series A · $77M8

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

People Similar to Rifat Pamukcu

Jeff HatfieldJeff HatfieldBoard Member · Vir BiotechnologyLouis PickerLouis PickerCo-Founder · Vir BiotechnologyMarianne De BackerMarianne De BackerBoard Member · Arrowhead Pharmaceuticals